iTeos 治疗学不优先化癌症药物 iTeos Therapeutics deprioritizes cancer drug Inupadenant despite positive trial results.

iTeos 治疗学提供了第2阶段试验中临时数据,用于Inupadenant(一种结合化疗药物的癌症治疗)。 iTeos Therapeutics presented interim data from its Phase 2 trial for Inupadenant, a cancer treatment combined with chemotherapy drugs. 综合调查显示,总体答复率为63.9%,中位数为7.7个月的无进展生存率。 The combination showed a 63.9% overall response rate and 7.7 months median progression-free survival. 建议的剂量显示,回复率为73.3%,6个月存活率为64.6%。 The recommended dose showed a 73.3% response rate and 64.6% six-month survival. 尽管取得了积极的成果,但由于临床活动不足,该公司决定将Inupadenant非优先化。 Despite positive results, the company decided to deprioritize Inupadenant due to insufficient clinical activity.